• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Therapy outcomes of IL-17 and JAK inhibitors in rosacea: A systematic review.

作者信息

Dai Xinyi, Zhang Chenxingyue, Yin Zhiqiang

机构信息

Department of Dermatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.

出版信息

J Biomed Res. 2024 Aug 21;39(3):317-318. doi: 10.7555/JBR.38.20240107.

DOI:10.7555/JBR.38.20240107
PMID:39164193
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12239976/
Abstract
摘要

相似文献

1
Therapy outcomes of IL-17 and JAK inhibitors in rosacea: A systematic review.IL-17和JAK抑制剂治疗酒渣鼻的疗效：一项系统评价。
J Biomed Res. 2024 Aug 21;39(3):317-318. doi: 10.7555/JBR.38.20240107.
2
Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review.Janus 激酶抑制剂在皮肌炎中的应用：系统文献综述。
Clin Exp Rheumatol. 2023 Mar;41(2):348-358. doi: 10.55563/clinexprheumatol/hxin6o. Epub 2022 Jun 28.
3
Biomarkers in rosacea: A systematic review.酒渣鼻的生物标志物：系统评价。
J Eur Acad Dermatol Venereol. 2024 Jun;38(6):1048-1057. doi: 10.1111/jdv.19732. Epub 2023 Dec 11.
4
Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis.JAK抑制剂对类风湿关节炎患者高密度脂蛋白和低密度脂蛋白的影响：一项系统评价和网状Meta分析
Clin Rheumatol. 2022 Mar;41(3):677-688. doi: 10.1007/s10067-021-06003-z. Epub 2022 Jan 7.
5
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials.Janus激酶抑制剂对因COVID-19住院成人患者的影响：一项随机临床试验的系统评价和个体参与者数据荟萃分析
Lancet Respir Med. 2025 Jun;13(6):530-544. doi: 10.1016/S2213-2600(25)00055-4. Epub 2025 May 13.
6
JAK inhibitors and systemic sclerosis: A systematic review of the literature.JAK 抑制剂与系统性硬化症：文献系统综述。
Autoimmun Rev. 2022 Oct;21(10):103168. doi: 10.1016/j.autrev.2022.103168. Epub 2022 Aug 6.
7
Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials.接受JAK-STAT抑制剂的皮肤科患者的短期心血管并发症：一项随机临床试验的荟萃分析
JAMA Dermatol. 2024 Mar 1;160(3):281-289. doi: 10.1001/jamadermatol.2023.5509.
8
Mechanisms and Recent Advances of Small-Molecule Therapeutics in Rosacea Treatment.小分子疗法治疗酒渣鼻的机制及最新进展
Clin Cosmet Investig Dermatol. 2025 Jun 12;18:1459-1470. doi: 10.2147/CCID.S525787. eCollection 2025.
9
Janus kinase inhibitors for the treatment of COVID-19.Janus 激酶抑制剂治疗 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 13;6(6):CD015209. doi: 10.1002/14651858.CD015209.
10
Systematic review of comparative studies on emerging psoriasis treatments: comparing biologics with biologics, small molecule inhibitors with small molecule inhibitors, and biologics with small molecule inhibitors.新兴银屑病治疗方法比较研究的系统评价：生物制剂与生物制剂、小分子抑制剂与小分子抑制剂以及生物制剂与小分子抑制剂的比较
Inflammopharmacology. 2025 May 29. doi: 10.1007/s10787-025-01758-2.

引用本文的文献

1
Advances in Genetic Polymorphism Research in Rosacea: Mechanisms and Clinical Implications.酒渣鼻遗传多态性研究进展：机制与临床意义
Clin Cosmet Investig Dermatol. 2025 Jun 5;18:1423-1429. doi: 10.2147/CCID.S524611. eCollection 2025.

本文引用的文献

1
Rosacea pathogenesis and therapeutics: current treatments and a look at future targets.酒渣鼻的发病机制与治疗：当前的治疗方法及对未来靶点的展望
Front Med (Lausanne). 2023 Dec 13;10:1292722. doi: 10.3389/fmed.2023.1292722. eCollection 2023.
2
Exploring the Pathogenesis and Mechanism-Targeted Treatments of Rosacea: Previous Understanding and Updates.探索酒渣鼻的发病机制及机制导向治疗：既往认识与更新
Biomedicines. 2023 Jul 31;11(8):2153. doi: 10.3390/biomedicines11082153.
3
Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways.酒渣鼻炎症浸润的分子和形态学特征揭示了Th1/Th17途径的激活。
J Invest Dermatol. 2015 Sep;135(9):2198-2208. doi: 10.1038/jid.2015.141. Epub 2015 Apr 7.
4
The effect of topical bevacizumab as an adjunctive therapy for corneal neovascularization.局部应用贝伐单抗作为角膜新生血管辅助治疗的效果。
Acta Ophthalmol. 2013 May;91(3):e246-8. doi: 10.1111/j.1755-3768.2012.02540.x. Epub 2012 Sep 23.
5
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.阿普米司特，一种环磷酸腺苷磷酸二酯酶-4 抑制剂，在体外和银屑病模型中表现出抗炎活性。
Br J Pharmacol. 2010 Feb;159(4):842-55. doi: 10.1111/j.1476-5381.2009.00559.x. Epub 2009 Dec 24.